Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s epilepsy forecast will answer the following questions:

  • Of all people with epilepsy, how many in each country have generalized-onset, partial-onset, or unknown-onset epilepsy?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of epilepsy over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following epilepsy patient populations:

  • Total prevalent cases of epilepsy.
  • Total prevalent cases of epilepsy by type of seizure.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Epilepsy | Disease Landscape and Forecast | G7 | 2025
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…
Report
Glaucoma – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of glaucoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…